Lower Dose of Abiraterone Acetate Proves Effective in Treating Prostate Cancer
A new study demonstrates that a lower, 500 mg daily dose of abiraterone acetate is as effective and safe as the standard dose for treating metastatic prostate cancer, potentially reducing side effects and costs.
Recent research conducted by scientists from the National University of Singapore (NUS) and the National University Hospital (NUH) suggests that a reduced dose of abiraterone acetate (AA), a drug commonly used in prostate cancer therapy, can be just as effective and safe as the standard high dose. Traditionally, the treatment involves a daily dose of 1000 mg, which can cause significant side effects and increase costs for patients. This new study explored whether a 500 mg daily dose, taken on an empty stomach, could deliver comparable therapeutic benefits.
The study involved nine men with metastatic prostate cancer. Results showed that patients receiving the lower dose experienced significant reductions in prostate-specific antigen (PSA) levels, a key marker of tumor activity, indicating effective cancer suppression. Both patient data and pharmacological modeling demonstrated that even at half the usual dosage, over 80% of the drug’s target enzyme, CYP17A1, remained inhibited, supporting the therapy's potency.
Findings were published in the journal Cancer Communications. The research indicates that lowering the dosage could reduce adverse side effects, lower treatment costs, and improve patient adherence. This approach could particularly benefit elderly patients or those with limited financial resources, making prostate cancer management more accessible.
Lead researcher Professor Eric Chan highlighted that all patients on the 500 mg regimen showed PSA reductions within 12 weeks, with more than 75% experiencing a decrease of 50% or more. The safety profile was favorable, with little to no significant side effects reported. The team has initiated larger, long-term trials to further validate these promising results.
This innovative, model-informed dosing strategy offers a potential shift in prostate cancer treatment, emphasizing cost-effectiveness and safety without compromising efficacy. Source: https://medicalxpress.com/news/2025-07-dose-abiraterone-acetate-effective-prostate.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Study Links Breathlessness to Increased Long-Term Mortality in Malawi
Research in Malawi links breathlessness with a high risk of death within a year, highlighting the need for integrated care in low-resource settings.
Innovative Approach to Developing a Universal Antiviral Therapy
A groundbreaking mRNA-based therapy aims to mimic a rare immune deficiency, providing broad protection against multiple viruses and paving the way for a universal antiviral treatment.
Pediatric Influenza-Associated Encephalopathy Highlights of 2024–2025 Season
The 2024–2025 flu season in the U.S. saw a rise in pediatric influenza-associated encephalopathy cases, including severe forms like ANE, with high hospitalization and mortality rates among children. Vaccination coverage remains crucial to prevent these severe outcomes.
Revolutionizing Genetic Research: How Generative AI Completes Microscopy Data Gaps
Skoltech researchers utilize generative AI to reconstruct missing DNA data in microscopy, unlocking new potential for genetic disease diagnosis and treatment.